David Liebner is an Oncology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 114 publications with 3,305 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
460 W 10th Ave
Columbus, OH 432101240
Telephone
614-293-6529Provider last certified this registry record 4 Dec 2020.
Clinical trials
- Niraparib for the Treatment of Leiomyosarcoma
Sponsor: David Liebner, MD
- An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry
Sponsor: Ohio State University Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Deciphera Pharmaceuticals Inc.Program year20251 payment
- Aadi Bioscience, Inc.Program year20242 payments
- Aadi Bioscience, Inc.Program year20233 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.1%Kinase inhibitor46.5%Sorafenib25%Pazopanib Hcl24%Verzenio21%Alecensa15%Votrient15%Part D<11 patientsGamma Secretase Inhibitor9.7%Ogsiveo100%Part D<11 patientsHormonal (systemic)
10.3%l-Thyroxine10.3%Levothyroxine Sodium100%Part D<11 patientsSensory organs
9.7%Corticosteroid9.7%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma
Journal of Clinical Oncology
2025 - Use of neoadjuvant paclitaxel in breast angiosarcoma—Impact on surgical resection and response rates
Journal of Surgical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ricardo Carrau, MD
The Ohio State University Comprehensive Cancer Center
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center
Steven Clinton, MD, PhD
The Ohio State University Comprehensive Cancer Center
Christian Rolfo, MD
The Ohio State University Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”